{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:41:03Z","timestamp":1788903663430,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82101994"],"award-info":[{"award-number":["No.82101994"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014869","name":"Chongqing Xinqiao Hospital, Second Affiliated Hospital of Army Medical University","doi-asserted-by":"publisher","award":["No. IIT-2022-015(HYX)"],"award-info":[{"award-number":["No. IIT-2022-015(HYX)"]}],"id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fluorine-18 fluorodeoxyglucose ([<jats:sup>18<\/jats:sup>F]FDG) positron emission tomography\/computed tomography (PET\/CT) has some limitations in diagnosis of Intrahepatic cholangiocarcinoma (ICC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Patients with histologically confirmed ICC who underwent both [<jats:sup>18<\/jats:sup>F]FDG and <jats:sup>18<\/jats:sup>F-labeled fibroblast-activation protein inhibitors ([<jats:sup>18<\/jats:sup>F]FAPI)-04 PET\/CT were prospectively analyzed. The maximum standard uptake value (SUV<jats:sub>max<\/jats:sub>), tumor-to-background ratio (TBR), metabolic tumor volume (MTV), total lesion glycolysis (TLG), [<jats:sup>18<\/jats:sup>F]FAPI\u2013avid tumor volume (FTV), total lesion fibroblast activation protein expression (TLF) were compared between the two modalities by paired Wilcoxon signed-rank test and Mann\u2013Whitney U test, and McNemar\u2019s test was used to assess the diagnostic accuracy between the two techniques.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 23 patients with 389 lesions were included. Compared to [<jats:sup>18<\/jats:sup>F]FDG, [<jats:sup>18<\/jats:sup>F]F-FAPI-04 PET\/CT demonstrated a higher detection rate for intrahepatic lesions (86.3% vs. 78.2% <jats:italic>P<\/jats:italic>\u2009=\u20090.040), lymph node metastases (85.2% vs. 68.2%, <jats:italic>P<\/jats:italic>\u2009=\u20090.007), peritoneal metastases (100% vs. 93.8%), and bone metastases (100% vs. 70.5%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). [<jats:sup>18<\/jats:sup>F]FAPI-04 PET showed higher SUV<jats:sub>max<\/jats:sub>, TBR and greater tumor burden values than [<jats:sup>18<\/jats:sup>F]FDG PET in non-cholangitis intrahepatic lesions (SUV<jats:sub>max<\/jats:sub>: 8.7 vs. 6.4, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; TBR: 8.0 vs. 3.5, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; FTV vs. MTV: 41.3 vs. 12.4, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; TLF vs. TLG: 223.5 vs. 57.0, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), lymph node metastases (SUV<jats:sub>max<\/jats:sub>: 6.5 vs. 5.5, <jats:italic>P<\/jats:italic>\u2009=\u20090.042; TBR: 5.4 vs. 3.9, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; FTV vs. MTV: 2.0 vs. 1.5, <jats:italic>P<\/jats:italic>\u2009=\u20090.026; TLF vs. TLG: 9.0 vs. 7.8 <jats:italic>P<\/jats:italic>\u2009=\u20090.024), and bone metastases (SUV<jats:sub>max<\/jats:sub>: 9.7 vs. 5.25, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; TBR: 10.8 vs. 3.0, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; TLF vs. TLG: 9.8 vs. 4.2, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). However, [<jats:sup>18<\/jats:sup>F]FDG showed higher radiotracer uptake (SUV<jats:sub>max<\/jats:sub>: 14.7 vs. 8.4, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001; TBR: 7.4 vs. 2.8, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) than [<jats:sup>18<\/jats:sup>F]FAPI-04 PET\/CT for 6 patients with obstructive cholangitis. [<jats:sup>18<\/jats:sup>F]FAPI-04 PET\/CT yielded a change in planned therapy in 6 of 23 (26.1%) patients compared with [<jats:sup>18<\/jats:sup>F]FDG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]FAPI-04 PET\/CT had higher detection rate and radiotracer uptake than [<jats:sup>18<\/jats:sup>F]FDG PET\/CT in intrahepatic lesions, lymph node metastases, and distant metastases, especially in bone. Therefore, [<jats:sup>18<\/jats:sup>F]FAPI-04 PET\/CT may be a promising technique for diagnosis and staging of ICC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Clinical Trials, NCT05485792. Registered 1 August 2022, retrospectively registered, https\/\/clinicaltrials.gov\/study\/NCT05485792?cond=NCT05485792&amp;rank=1.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13550-024-01145-y","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:31:03Z","timestamp":1726025463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Role of [18F]FAPI-04 in staging and therapeutic management of intrahepatic cholangiocarcinoma: prospective comparison with [18F]FDG PET\/CT"],"prefix":"10.1186","volume":"14","author":[{"given":"Jiucen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojuan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songquan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-6300","authenticated-orcid":false,"given":"Linqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"1145_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1145_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2015.09.008","volume":"379","author":"H Zhang","year":"2016","unstructured":"Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2016;379:198\u2013205. https:\/\/doi.org\/10.1016\/j.canlet.2015.09.008.","journal-title":"Cancer Lett"},{"key":"1145_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7.","journal-title":"Lancet"},{"key":"1145_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jso.21811","volume":"103","author":"S Kobayashi","year":"2011","unstructured":"Kobayashi S, Nagano H, Hoshino H, Wada H, Marubashi S, Eguchi H, et al. Diagnostic value of FDG-PET for lymph node metastasis and outcome of surgery for biliary cancer. J Surg Oncol. 2011;103:223\u20139. https:\/\/doi.org\/10.1002\/jso.21811.","journal-title":"J Surg Oncol"},{"key":"1145_CR5","doi-asserted-by":"publisher","first-page":"e20932","DOI":"10.1097\/md.0000000000020932","volume":"99","author":"X Huang","year":"2020","unstructured":"Huang X, Yang J, Li J, Xiong Y. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography\/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma. Medicine. 2020;99:e20932. https:\/\/doi.org\/10.1097\/md.0000000000020932.","journal-title":"Medicine"},{"key":"1145_CR6","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.suronc.2009.08.003","volume":"20","author":"CM Moon","year":"2011","unstructured":"Moon CM, Bang S, Chung JB. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma. Surg Oncol. 2011;20:e10\u20137. https:\/\/doi.org\/10.1016\/j.suronc.2009.08.003.","journal-title":"Surg Oncol"},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13139-016-0440-y","volume":"51","author":"Y Lee","year":"2017","unstructured":"Lee Y, Yoo IR, Boo SH, Kim H, Park HL, Hyun OJ. The role of F-18 FDG PET\/CT in Intrahepatic Cholangiocarcinoma. Nucl Med Mol Imaging. 2017;51:69\u201378. https:\/\/doi.org\/10.1007\/s13139-016-0440-y.","journal-title":"Nucl Med Mol Imaging"},{"key":"1145_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jhep.2019.01.038","volume":"71","author":"A Lamarca","year":"2019","unstructured":"Lamarca A, Barriuso J, Chander A, McNamara MG, Hubner RA, \u00d3Reilly D, et al. 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: systematic review and meta-analysis. J Hepatol. 2019;71:115\u201329. https:\/\/doi.org\/10.1016\/j.jhep.2019.01.038.","journal-title":"J Hepatol"},{"key":"1145_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00535-013-0790-5","volume":"49","author":"M Tsurusaki","year":"2014","unstructured":"Tsurusaki M, Okada M, Kuroda H, Matsuki M, Ishii K, Murakami T. Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor. J Gastroenterol. 2014;49:46\u201356. https:\/\/doi.org\/10.1007\/s00535-013-0790-5.","journal-title":"J Gastroenterol"},{"key":"1145_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, et al. [18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. Eur J Nucl Med Mol Imaging. 2023;50:937\u201350. https:\/\/doi.org\/10.1007\/s00259-022-06022-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR11","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","volume":"48","author":"L Zhao","year":"2021","unstructured":"Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944\u201355. https:\/\/doi.org\/10.1007\/s00259-020-05146-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrgastro.2011.222","volume":"9","author":"AE Sirica","year":"2011","unstructured":"Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;9:44\u201354. https:\/\/doi.org\/10.1038\/nrgastro.2011.222.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1145_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13058-016-0740-2","volume":"18","author":"KM Bussard","year":"2016","unstructured":"Bussard KM, Mutkus L, Stumpf K, Gomez-Manzano C, Marini FC. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res. 2016;18:84. https:\/\/doi.org\/10.1186\/s13058-016-0740-2.","journal-title":"Breast Cancer Res"},{"key":"1145_CR14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.244806.","journal-title":"J Nucl Med"},{"key":"1145_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","volume":"64","author":"KM Pabst","year":"2023","unstructured":"Pabst KM, Trajkovic-Arsic M, Cheung PFY, Ballke S, Steiger K, Bartel T, et al. Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET\/CT and conventional CT in patients with Cholangiocarcinoma. J Nucl Med. 2023;64:1049\u201355. https:\/\/doi.org\/10.2967\/jnumed.122.265215.","journal-title":"J Nucl Med"},{"key":"1145_CR16","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","volume":"48","author":"X Shi","year":"2020","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2020;48:1593\u2013603. https:\/\/doi.org\/10.1007\/s00259-020-05070-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2967\/jnumed.123.266329","volume":"65","author":"W Xu","year":"2024","unstructured":"Xu W, Cai J, Peng T, Meng T, Pang Y, Sun L, et al. Fibroblast activation protein-targeted PET\/CT with 18F-Fibroblast activation protein Inhibitor-74 for evaluation of gastrointestinal Cancer: comparison with 18F-FDG PET\/CT. J Nucl Med. 2024;65:40\u201351. https:\/\/doi.org\/10.2967\/jnumed.123.266329.","journal-title":"J Nucl Med"},{"key":"1145_CR18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","volume":"48","author":"W Guo","year":"2021","unstructured":"Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1604\u201317. https:\/\/doi.org\/10.1007\/s00259-020-05095-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR19","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00259-023-06137-z","volume":"50","author":"L Jinghua","year":"2023","unstructured":"Jinghua L, Kui X, Deliang G, Bo L, Qian Z, Haitao W, et al. Clinical prospective study of Gallium 68 (68Ga)\u2013labeled fibroblast-activation protein inhibitor PET\/CT in the diagnosis of biliary tract carcinoma. Eur J Nucl Med Mol Imaging. 2023;50:2152\u201366. https:\/\/doi.org\/10.1007\/s00259-023-06137-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s00066-023-02117-2","volume":"200","author":"S Wegen","year":"2024","unstructured":"Wegen S, Weindler J, Voltin CA, van Heek L, Schom\u00e4cker K, Fischer T, et al. Dual-tracer PET\/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET\/CT with [18F]FDG in different cancer types, resulting in larger functional and gross tumor volume. Strahlenther Onkol. 2024;200:28\u201338. https:\/\/doi.org\/10.1007\/s00066-023-02117-2.","journal-title":"Strahlenther Onkol"},{"key":"1145_CR21","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","volume":"64","author":"M Wu","year":"2023","unstructured":"Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H, et al. Comparison of baseline 68Ga-FAPI and 18F-FDG PET\/CT for prediction of response and clinical outcome in patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 inhibitor and Lenvatinib. J Nucl Med. 2023;64:1532\u201339. https:\/\/doi.org\/10.2967\/jnumed.123.265712.","journal-title":"J Nucl Med"},{"key":"1145_CR22","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1007\/s00259-023-06137-z","volume":"49","author":"K Hu","year":"2022","unstructured":"Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q, et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2022;49:2833\u201343. https:\/\/doi.org\/10.1007\/s00259-023-06137-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR23","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [18F] AlFNOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET\/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-022-05758-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR24","doi-asserted-by":"publisher","unstructured":"Amin M. AJCC Cancer Staging Manual (8th ed.). American Joint Committee on Cancer; 2017. https:\/\/doi.org\/10.1007\/978-3-319-40618-3_1","DOI":"10.1007\/978-3-319-40618-3_1"},{"key":"1145_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40644-023-00626-y","volume":"23","author":"J Zhang","year":"2023","unstructured":"Zhang J, Jiang S, Li M, Xue H, Zhong X, Li S, et al. Head-to-head comparison of 18F-FAPI and 18F-FDG PET\/CT in staging and therapeutic management of hepatocellular carcinoma. Cancer Imaging. 2023;23:106. https:\/\/doi.org\/10.1186\/s40644-023-00626-y.","journal-title":"Cancer Imaging"},{"key":"1145_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RLU.0000000000000998","volume":"41","author":"L Jiang","year":"2016","unstructured":"Jiang L, Tan H, Panje CM, Yu H, Xiu Y, Shi H. Role of 18F-FDG PET\/CT imaging in Intrahepatic Cholangiocarcinoma. Clin Nucl Med. 2016;41:1\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000000998.","journal-title":"Clin Nucl Med"},{"key":"1145_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/jim-2017-000472","volume":"66","author":"JH Hu","year":"2018","unstructured":"Hu JH, Tang JH, Lin CH, Chu YY, Liu NJ. Preoperative staging of cholangiocarcinoma and biliary carcinoma using 18F-fluorodeoxyglucose positron emission tomography: a meta-analysis. J Invest Medicine: Official Publication Am Federation Clin Res. 2018;66:52\u201361. https:\/\/doi.org\/10.1136\/jim-2017-000472.","journal-title":"J Invest Medicine: Official Publication Am Federation Clin Res"},{"key":"1145_CR28","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-003-1297-8","volume":"30","author":"YJ Kim","year":"2003","unstructured":"Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1467\u201372. https:\/\/doi.org\/10.1007\/s00259-003-1297-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1145_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1148\/radiol.213118","volume":"304","author":"L Lan","year":"2022","unstructured":"Lan L, Zhang S, Xu T, Liu H, Wang W, Feng Y, et al. Prospective comparison of 68Ga-FAPI versus 18F-FDG PET\/CT for Tumor staging in biliary tract cancers. Radiology. 2022;304:648\u201357. https:\/\/doi.org\/10.1148\/radiol.213118.","journal-title":"Radiology"},{"key":"1145_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/RLU.0000000000002914","volume":"45","author":"Y Luo","year":"2020","unstructured":"Luo Y, Pan Q, Zhang W, Li F. Intense FAPI uptake in inflammation may mask the Tumor activity of pancreatic Cancer in 68Ga-FAPI PET\/CT. Clin Nucl Med. 2020;45:310\u201311. https:\/\/doi.org\/10.1097\/RLU.0000000000002914.","journal-title":"Clin Nucl Med"},{"key":"1145_CR31","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","volume":"29","author":"MC de Jong","year":"2011","unstructured":"de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29:3140\u20135. https:\/\/doi.org\/10.1200\/JCO.2011.35.6519.","journal-title":"J Clin Oncol"},{"key":"1145_CR32","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1097\/RLU.0000000000004833","volume":"48","author":"Q Shu","year":"2023","unstructured":"Shu Q, He X, Chen X, Liu M, Chen Y, Cai L. Head-to-Head comparison of 18 F-FDG and 68 Ga-FAPI-04 PET\/CT for Radiological evaluation of Cervical Cancer. Clin Nucl Med. 2023;48:928\u201332. https:\/\/doi.org\/10.1097\/RLU.0000000000004833.","journal-title":"Clin Nucl Med"},{"key":"1145_CR33","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/RLU.0000000000003939","volume":"47","author":"Q Shang","year":"2022","unstructured":"Shang Q, Zhao L, Pang Y, Yu Y, Chen H. 68Ga-FAPI PET\/CT distinguishes the reactive lymph nodes from Tumor Metastatic Lymph nodes in a patient with nasopharyngeal carcinoma. Clin Nucl Med. 2022;47:367\u201368. https:\/\/doi.org\/10.1097\/RLU.0000000000003939.","journal-title":"Clin Nucl Med"},{"key":"1145_CR34","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/RLU.0000000000003998","volume":"47","author":"Q Shang","year":"2022","unstructured":"Shang Q, Zhao L, Pang Y, Meng T, Chen H. Differentiation of reactive lymph nodes and Tumor Metastatic Lymph Nodes with 68Ga-FAPI PET\/CT in a patient with squamous cell Lung Cancer. Clin Nucl Med. 2022;47:458\u201361. https:\/\/doi.org\/10.1097\/RLU.0000000000003998.","journal-title":"Clin Nucl Med"},{"key":"1145_CR35","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.2967\/jnumed.123.265751","volume":"64","author":"TT Demmert","year":"2023","unstructured":"Demmert TT, Pomykala KL, Lanzafame H, Pabst KM, Lueckerath K, Siveke J, et al. Oncologic staging with 68Ga-FAPI PET\/CT demonstrates a lower rate of nonspecific Lymph Node findings Than 18F-FDG PET\/CT. J Nucl Med. 2023;64:1906\u201309. https:\/\/doi.org\/10.2967\/jnumed.123.265751.","journal-title":"J Nucl Med"},{"key":"1145_CR36","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00330-022-09084-9","volume":"33","author":"H Chen","year":"2023","unstructured":"Chen H, Pang Y, Li J, Kang F, Xu W, Meng T, et al. Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicenter retrospective study. Eur Radiol. 2023;33:1329\u201341. https:\/\/doi.org\/10.1007\/s00330-022-09084-9.","journal-title":"Eur Radiol"},{"key":"1145_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2214\/AJR.22.28402","volume":"220","author":"Z Gege","year":"2023","unstructured":"Gege Z, Xueju W, Bin J. Head-To-Head comparison of 68Ga-FAPI PET\/CT and FDG PET\/CT for the detection of peritoneal metastases: systematic review and Meta-analysis. AJR Am J Roentgenol. 2023;220:490\u201398. https:\/\/doi.org\/10.2214\/AJR.22.28402.","journal-title":"AJR Am J Roentgenol"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-024-01145-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-024-01145-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T03:45:40Z","timestamp":1726026340000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-024-01145-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1186\/s13550-024-01145-y","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Affiliated Cancer Hospital & Institute of Guangzhou Medical University (ethics committee approval No. 2021-sw07).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants (signed by participant, parent, or legal representative) included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}